Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii - PubMed (original) (raw)
Review
. 2007 Jul;41(7):1212-21.
doi: 10.1345/aph.1K110. Epub 2007 Jun 26.
Affiliations
- PMID: 17595306
- DOI: 10.1345/aph.1K110
Review
Probiotics for Clostridium difficile-associated diarrhea: focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii
Marisel Segarra-Newnham. Ann Pharmacother. 2007 Jul.
Abstract
Objective: To review the literature on the use of probiotics to treat or prevent recurrences of Clostridium difficile-associated diarrhea (CDAD) by replacing normal gastric flora.
Data sources: PubMed (1970-March 2007) was searched using the terms probiotics, Clostridium difficile, colitis, diarrhea, prevention, and treatment.
Study selection and data extraction: Case reports, case series, and clinical trials describing the use of probiotics in the treatment or prevention of recurrences of CDAD as primary outcome were included.
Data synthesis: A variety of controlled trials, case series, and case reports have evaluated probiotics to treat first or recurrent episodes of CDAD. In addition, a meta-analysis has been conducted to try to determine the role of probiotics in CDAD. In general, most case series and case reports have shown favorable results with Lactobacillus rhamnosus GG or Saccharomyces boulardii. However, other reports have shown lack of benefit. The meta-analysis showed that these probiotics may be useful in treating or preventing recurrences of CDAD. Nonetheless, the heterogeneity of the studies makes definite conclusions difficult. In addition, several cases of bacteremia or fungemia associated with probiotic use have been reported, particularly in the last decade. Patients most commonly affected by these complications are immunosuppressed. Unfortunately, these are also the patients more likely to have severe CDAD or are at risk for recurrences.
Conclusions: Additional experience with and study of probiotics are warranted due to numerous unanswered questions. Given the potential for complications in debilitated and immunosuppressed patients, the risks may outweigh benefits, and rational antibiotic use may be a better option to prevent a first episode or recurrence of CDAD.
Comment in
- Probiotics for Clostridium difficile diarrhea: putting it into perspective.
Karpa KD. Karpa KD. Ann Pharmacother. 2007 Jul;41(7):1284-7. doi: 10.1345/aph.1K228. Epub 2007 Jun 26. Ann Pharmacother. 2007. PMID: 17595302
Similar articles
- Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease.
McFarland LV. McFarland LV. Am J Gastroenterol. 2006 Apr;101(4):812-22. doi: 10.1111/j.1572-0241.2006.00465.x. Am J Gastroenterol. 2006. PMID: 16635227 - Past, present, and future therapies for Clostridium difficile-associated disease.
Surowiec D, Kuyumjian AG, Wynd MA, Cicogna CE. Surowiec D, et al. Ann Pharmacother. 2006 Dec;40(12):2155-63. doi: 10.1345/aph.1H332. Epub 2006 Dec 5. Ann Pharmacother. 2006. PMID: 17148650 Review. - Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent episodes?
Imhoff A, Karpa K. Imhoff A, et al. Nutr Clin Pract. 2009 Feb-Mar;24(1):15-32. doi: 10.1177/0884533608329232. Nutr Clin Pract. 2009. PMID: 19244145 Review. - Probiotics for prevention and treatment of diarrhea.
Guandalini S. Guandalini S. J Clin Gastroenterol. 2011 Nov;45 Suppl:S149-53. doi: 10.1097/MCG.0b013e3182257e98. J Clin Gastroenterol. 2011. PMID: 21992955 Review. - Lactobacillus and bifidobacteria combinations: a strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality.
Graul T, Cain AM, Karpa KD. Graul T, et al. Med Hypotheses. 2009 Aug;73(2):194-8. doi: 10.1016/j.mehy.2009.02.026. Epub 2009 Apr 8. Med Hypotheses. 2009. PMID: 19359104
Cited by
- Bacteraemia Caused by Probiotic Strains of _Lacticaseibacillus rhamnosus_-Case Studies Highlighting the Need for Careful Thought before Using Microbes for Health Benefits.
Mikucka A, Deptuła A, Bogiel T, Chmielarczyk A, Nurczyńska E, Gospodarek-Komkowska E. Mikucka A, et al. Pathogens. 2022 Aug 26;11(9):977. doi: 10.3390/pathogens11090977. Pathogens. 2022. PMID: 36145409 Free PMC article. - Lactobacillus rhamnosus GG ameliorates DON-induced intestinal damage depending on the enrichment of beneficial bacteria in weaned piglets.
Bai Y, Ma K, Li J, Ren Z, Zhang J, Shan A. Bai Y, et al. J Anim Sci Biotechnol. 2022 Aug 12;13(1):90. doi: 10.1186/s40104-022-00737-9. J Anim Sci Biotechnol. 2022. PMID: 35962456 Free PMC article. - Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.
Rao K, Higgins PD. Rao K, et al. Inflamm Bowel Dis. 2016 Jul;22(7):1744-54. doi: 10.1097/MIB.0000000000000793. Inflamm Bowel Dis. 2016. PMID: 27120571 Free PMC article. Review. - Lactobacillus rhamnosus GG Intake Modifies Preschool Children's Intestinal Microbiota, Alleviates Penicillin-Associated Changes, and Reduces Antibiotic Use.
Korpela K, Salonen A, Virta LJ, Kumpu M, Kekkonen RA, de Vos WM. Korpela K, et al. PLoS One. 2016 Apr 25;11(4):e0154012. doi: 10.1371/journal.pone.0154012. eCollection 2016. PLoS One. 2016. PMID: 27111772 Free PMC article. Clinical Trial. - Importance of Molecular Methods to Determine Whether a Probiotic is the Source of Lactobacillus Bacteremia.
Aroutcheva A, Auclair J, Frappier M, Millette M, Lolans K, de Montigny D, Carrière S, Sokalski S, Trick WE, Weinstein RA. Aroutcheva A, et al. Probiotics Antimicrob Proteins. 2016 Mar;8(1):31-40. doi: 10.1007/s12602-016-9209-y. Probiotics Antimicrob Proteins. 2016. PMID: 26915093
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical